SOPHiA GENETICS SA Annual Meeting Approves 2023 Financials

Ticker: SOPH · Form: 6-K · Filed: 2024-06-25T00:00:00.000Z

Sentiment: neutral

Topics: annual-meeting, financial-statements, corporate-governance

Related Tickers: SOPH

TL;DR

SOPHIA GENETICS (SOPH) shareholders greenlit the 2023 financials at the June 24th annual meeting.

AI Summary

SOPHiA GENETICS SA held its annual general meeting on June 24, 2024. Shareholders approved the 2023 Management Report, Annual Financial Statements, and Consolidated Financial Statements, along with acknowledging the Auditors' Reports. The company is a foreign private issuer filing under Form 20-F.

Why It Matters

Shareholder approval of financial statements is a routine but important step in corporate governance, confirming the accuracy of the company's reported performance.

Risk Assessment

Risk Level: low — This filing is a routine update on the results of an annual general meeting and does not contain new material financial or strategic information.

Key Players & Entities

FAQ

What was the primary purpose of the June 24, 2024 filing?

The filing was a Form 6-K reporting the final results of SOPHiA GENETICS SA's annual general meeting held on June 24, 2024.

Which financial statements were approved by shareholders?

Shareholders approved the 2023 Management Report, the Annual Financial Statements, and the Consolidated Financial Statements for the financial year 2023.

Did the shareholders acknowledge the auditors' reports?

Yes, the shareholders acknowledged the Auditors' Reports.

What form does SOPHiA GENETICS SA file annually?

SOPHiA GENETICS SA indicates it files annual reports under cover of Form 20-F.

Where is SOPHiA GENETICS SA's principal executive office located?

The principal executive office is located at La Pièce 12, CH-1180 Rolle, Switzerland.

Filing Stats: 1,455 words · 6 min read · ~5 pages · Grade level 8.4 · Accepted 2024-06-25 13:38:20

Filing Documents

Financial Statements and the Consolidated Financial Statements for the financial year 2023

Financial Statements and the Consolidated Financial Statements for the financial year 2023 and acknowledged the Auditors’ Reports. The shareholders approved the proposal of the Board of Directors on this item with 39,464,838 votes (99.82% of all ordinary shares represented) in favor, 5,192 votes (0.01%) against and 67,565 (0.17%) abstentions. · Item 2: Consultative vote on the 2023 ESG Impact Summary (Sustainability Report) . The shareholders approved the proposal of the Board of Directors on this item with 39,503,166 (consultative) votes (99.91% of all ordinary shares represented) in favor, 27,020 votes (0.07%) against and 7,409 (0.02%) abstentions. · Item 3: Discharge of the members of the Board of Directors and the Executive Committee . The shareholders approved the discharge of the members of the Board of Directors and the Executive Committee from liability for the financial year 2023. The shareholders approved the proposal of the Board of Directors on this item with 35,559,798 votes (99.76% of all ordinary shares represented) in favor, 25,244 votes (0.06%) against and 69,729 (0.18%) abstentions. · Item 4: Appropriation of 2023 Financial Results . The shareholders approved that the net loss of the Company for the financial year 2023 in the amount of CHF 58,130,396 be carried forward, resulting in a total loss of CHF 311,338,505 to be carried forward. The shareholders approved this item with 39,510,602 votes (99.93% of all ordinary shares represented) in favor, 4,020 votes (0.01%) against and 22,973 (0.06%) abstentions. · Item 5: Re-election of the Chair; re-election of the Members of the Board of Directors . The shareholders approved the re-election of the following members of the Board of Directors, including the Chair, for a term of office until the completion of the 2025 Annual General Meeting. Lila Tretikov did not stand for re-election. a. The shareholders approved the re-election of Troy Cox with 38,893,775 votes

View on Read The Filing